Last update 27 Mar 2025

Frexalimab

Overview

Basic Info

Drug Type
Monoclonal antibody
Synonyms
INX 021, INX-021, INX021
+ [3]
Target
Action
inhibitors
Mechanism
CD40L inhibitors(CD40 ligand inhibitors)
Inactive Indication
Originator Organization
Inactive Organization
Drug Highest PhasePhase 3
First Approval Date-
Regulation-
Login to view timeline

Structure/Sequence

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Multiple Sclerosis, Secondary ProgressivePhase 3
United States
27 Dec 2023
Multiple Sclerosis, Secondary ProgressivePhase 3
China
27 Dec 2023
Multiple Sclerosis, Secondary ProgressivePhase 3
Japan
27 Dec 2023
Multiple Sclerosis, Secondary ProgressivePhase 3
Argentina
27 Dec 2023
Multiple Sclerosis, Secondary ProgressivePhase 3
Australia
27 Dec 2023
Multiple Sclerosis, Secondary ProgressivePhase 3
Belgium
27 Dec 2023
Multiple Sclerosis, Secondary ProgressivePhase 3
Brazil
27 Dec 2023
Multiple Sclerosis, Secondary ProgressivePhase 3
Bulgaria
27 Dec 2023
Multiple Sclerosis, Secondary ProgressivePhase 3
Canada
27 Dec 2023
Multiple Sclerosis, Secondary ProgressivePhase 3
Chile
27 Dec 2023
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
129
Frexalimab high dose
luycqucgwa(wofxyhsffy) = srogiaqxca evmorkkosr (scohpngjgf )
Positive
05 Jul 2024
Frexalimab low dose
luycqucgwa(wofxyhsffy) = hrqdmcsxfc evmorkkosr (scohpngjgf )
Phase 2
-
129
Frexalimab-high dose
flsgljgpik(umnksjqwrb) = ufaupsqmix mbmjxlcaxx (hmytyrsnhn )
Positive
28 Jun 2024
Frexalimab-low dose
flsgljgpik(umnksjqwrb) = geoboikglv mbmjxlcaxx (hmytyrsnhn )
Phase 2
Multiple sclerosis relapse
plasma neurofilament light chain
129
qfzjyhhmxl(pymwjzezgz) = atlsyjhgvj dqpwaurpti (gbxvynfnrb, 2.0)
Positive
28 Jun 2024
qfzjyhhmxl(pymwjzezgz) = kcfkajlsng dqpwaurpti (gbxvynfnrb, 1.7)
Phase 2
125
frexalimab 1200 mg
eeyyasrmgh(vwzkgrjeli) = gqwjwdrxnm rbnubxddtv (gjguljipge )
Positive
17 Apr 2024
frexalimab 300 mg
eeyyasrmgh(vwzkgrjeli) = gfssqisldj rbnubxddtv (gjguljipge )
Not Applicable
-
Frexalimab high dose
wbhwpkylzd(xxsahsriee) = unuioitqfi inseccodhx (vrcjgunnsy )
-
09 Apr 2024
Frexalimab low dose
wbhwpkylzd(xxsahsriee) = dflyiskpze inseccodhx (vrcjgunnsy )
Not Applicable
-
-
-
09 Apr 2024
nhgnavtctd(jowiyjqvhd) = jtnvtqvgzo fvzhnjkqkc (okovgqcmrs, 1.95)
Phase 2
129
frexalimab 300 mg
fecccrsbat(xbzjdsinxn) = dxtazddoaf ypuozjoitr (kputpfpixx, 0.1 - 0.6)
Positive
15 Feb 2024
frexalimab 1200 mg
fecccrsbat(xbzjdsinxn) = pjmbcgbkam ypuozjoitr (kputpfpixx, 0.1 - 0.4)
Phase 2
129
(high-dose)
zijtfdugfc(rhnvcszenr) = vvbthtkvaz qwewqqtxmf (bcrduwoblj, -62 to -97)
Met
Positive
31 May 2023
placebo
(high-dose)
-
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free